The first 17 amino acids of huntingtin (NT17 domain) has been implicated as a critical regulator of mutant huntingtin (mhtt) mediated disease pathogenesis in Huntington's disease (HD). In the current study, we created a novel BAC mouse model of HD expressing full-length mhtt lacking this domain (BACHD-dNT17), and showed that these mice exhibit accelerated nuclear mhtt accumulation (hence supporting its role as a cytoplasmic retention signal in vivo), and exacerbate HD-like disease pathogenesis including movement disorder and striatal neurodegeneration. Based on these exciting findings, we hypothesize that the NT17 domain and its cytoplasmic interactors are critical in preventing mhtt nuclear accumulation and HD-like disease pathogenesis in vivo. To test this hypothesis, we proposed the following two Aims:
Aim One. Using independent transgenic mouse lines to show the NT17 domain can prevent nuclear mhtt accumulation and HD-like disease pathogenesis in a polyQ-length dependent manner in vivo.
Aim Two. Validating novel NT17 interacting proteins as cytoplasmic acceptors that mediate NT17- dependent htt cytoplasmic retention in cell models, and one such interactor, Tcp1, as modifier of HD pathogenesis in vivo. Our study may provide novel therapeutic insights based on the NT17 domain and its interacting proteins to ameliorate nuclear mhtt toxicity and prevent the onset of movement disorder and neurodegeneration in HD.
Huntington's disease (HD) is a common inherited fatal neurodegenerative disorder that is characterized by progressive motor, cognitive, and psychiatric symptoms. Our proposed study is based on the surprising finding that deletion of the first 17 amino acids of mutant huntingtin (NT17 domain) leads to accelerated nuclear mutant huntingtin accumulation and triggers HD-like movement disorder and neurodegeneration. Elucidating the precise underlying molecular mechanisms through which the NT17 domain and its molecular interactors can suppress HD pathogenesis in mouse genetic models may provide novel therapeutic targets for HD.
|Kratter, Ian H; Zahed, Hengameh; Lau, Alice et al. (2016) Serine 421 regulates mutant huntingtin toxicity and clearance in mice. J Clin Invest 126:3585-97|
|Langfelder, Peter; Cantle, Jeffrey P; Chatzopoulou, Doxa et al. (2016) Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci 19:623-33|
|Estrada-SÃ¡nchez, Ana MarÃa; Burroughs, Courtney L; Cavaliere, Stephen et al. (2015) Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease. J Neurosci 35:4440-51|
|Gu, Xiaofeng; Cantle, Jeffrey P; Greiner, Erin R et al. (2015) N17 Modifies mutant Huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic mice. Neuron 85:726-41|
|PeÃ±agarikano, Olga; LÃ¡zaro, MarÃa T; Lu, Xiao-Hong et al. (2015) Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism. Sci Transl Med 7:271ra8|
|Veldman, Matthew B; Rios-Galdamez, Yesenia; Lu, Xiao-Hong et al. (2015) The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington's disease model. Mol Neurodegener 10:67|
|Lu, Xiao-Hong; Mattis, Virginia B; Wang, Nan et al. (2014) Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease. Sci Transl Med 6:268ra178|
|Haustein, Martin D; Kracun, Sebastian; Lu, Xiao-Hong et al. (2014) Conditions and constraints for astrocyte calcium signaling in the hippocampal mossy fiber pathway. Neuron 82:413-29|
|Wang, Nan; Gray, Michelle; Lu, Xiao-Hong et al. (2014) Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat Med 20:536-41|
|Lee, C Y Daniel; Cantle, Jeffrey P; Yang, X William (2013) Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J 280:4382-94|
Showing the most recent 10 out of 15 publications